NCT00793026

CompletedPhase 3

Dermacyd Breeze Pocket BR (Lactic Acid) - Acceptability

Sanofi Source

Compare

Other study identifiers

Sponsor study identifier

LACAC_L_04365

Study Type

interventional

Actual enrollment (reported)

30

Locations

1 country

Sites

1

Timeline

Study Start

November 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

November 2008

Actual (reported)

Study Completion

Not reported

Date not reported

Brief Summary

The purpose of this study is to prove the safety of the gynaecological formulation in normal conditions of use.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 30 participants
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
November 2008
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
November 2008
Actual (reported)
First Submitted
November 17, 2008
Actual (reported)
First Posted
November 18, 2008
Actual (reported)

Last Updated: December 19, 2008
Status Verified: December 2008
Last Update Submitted: December 18, 2008

Conditions

Hygiene

Outcome Measures

Primary Outcomes (2)

Absence of irritation
Throughout the study
Good acceptability
Throughout the study

Study Arms (1)

1

EXPERIMENTAL

Dermacyd Breeze Pocket BR (Lactic Acid)

Drug: Dermacyd Breeze Pocket BR (Lactic Acid)

Interventions

Dermacyd Breeze Pocket BR (Lactic Acid)Drug

Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days

1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 60 Years

Sexfemale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Integral skin test in the region;
To use products of the same category;

You may not qualify if:

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (1)

Sanofi-Aventis Administrative Office

São Paulo, Brazil

MeSH Terms

Interventions

Lactic Acid

Intervention Hierarchy (Ancestors)

LactatesHydroxy AcidsCarboxylic AcidsOrganic Chemicals

Study Officials

Jaderson Lima
Sanofi
STUDY DIRECTOR

Enrollment

30 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: SUPPORTIVE CARE
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

November 17, 2008

First Posted

November 18, 2008

Study Start

November 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00783640

Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation

Phase 3Completed

NCT00664391

Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze

Phase 3Completed

NCT00785148

Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety

Phase 3Completed

NCT00785642

Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.

Phase 3Completed

NCT00933699

Dermacyd PH_DESILSTY_FL (Lactic Acid) - Acceptability - Stay on Floral.

Phase 3Completed

NCT00933413

Dermacyd Silver Frutal (Lactic Acid) - Acceptability.

Phase 3Completed

Lactation or gestation;
Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs;
Cutaneous disease (local or spread) in the evaluation area;
Pathology which may cause immunity depression, such as HIV, diabetes;
Endocrine pathology
Solar exposure 15 days before evaluation;
Treatment until four months before the selection.
Allergic or atopic history to cosmetics products
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contact the study team to confirm eligibility.

Primary Completion

November 2008

Actual (reported)

Last Updated

December 19, 2008

Record last verified: 2008-12

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00793026
Data provider: ClinicalTrials.gov
Source updated: 2008-12-19
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:14 UTC

Locations

BR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations